About the Company
alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ALKS News
Insider Sell: SVP, Chief Commercial Officer Christian Nichols Sells Shares of Alkermes PLC (ALKS)
Alkermes PLC (NASDAQ:ALKS), a global biopharmaceutical company, is focused on developing innovative medicines that address ...
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent ...
Alkermes plc (ALKS) Q4 2023 Earnings Call Transcript
Sandy, you may begin. Thank you, Rob. Good morning. Welcome to the Alkermes plc conference call to discuss our financial results and business update for the quarter and year ended December 31 ...
Alkermes PLC
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Alkermes: Q4 Earnings Snapshot
DUBLIN (AP) — DUBLIN (AP) — Alkermes PLC (ALKS) on Thursday reported fourth-quarter net income of $112.8 million, after reporting a loss in the same period a year earlier. The Dublin-based ...
Alkermes Announces Interim Financial Leadership Appointments
Alkermes plc has appointed Blair C. Jackson as interim principal financial officer and Samuel J. Parisi as interim principal accounting officer during Iain M. Brown’s medical leave. Jackson ...
Alkermes plc Q4 Earnings Summary
(RTTNews) - Below are the earnings highlights for Alkermes plc (ALKS): Earnings: $112.78 million in Q4 vs. -$28.25 million in the same period last year. EPS: $0.66 in Q4 vs. -$0.17 in the same ...
Loading the latest forecasts...